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Abstract
Hirschsprung disease (HSCR, OMIM 142623) is a developmental disorder characterized by the absence of ganglion cells
along variable lengths of the distal gastrointestinal tract, which results in tonic contraction of the aganglionic colon
segment and functional intestinal obstruction. The RET proto-oncogene is the major gene associated to HSCR with
differential contributions of its rare and common, coding and noncoding mutations to the multifactorial nature of this
pathology. In addition, many other genes have been described to be associated with this pathology, including the
semaphorins class III genes SEMA3A (7p12.1) and SEMA3D (7q21.11) through SNP array analyses and by next-generation
sequencing technologies. Semaphorins are guidance cues for developing neurons implicated in the axonal projections and
in the determination of the migratory pathway for neural-crest derived neural precursors during enteric nervous system
development. In addition, it has been described that increased SEMA3A expression may be a risk factor for HSCR through
the upregulation of the gene in the aganglionic smooth muscle layer of the colon in HSCR patients. Here we present the
results of a comprehensive analysis of SEMA3A and SEMA3D in a series of 200 Spanish HSCR patients by the mutational
screening of its coding sequence, which has led to find a number of potentially deleterious variants. RET mutations have
been also detected in some of those patients carrying SEMAs variants. We have evaluated the A131T-SEMA3A, S598G-
SEMA3A and E198K-SEMA3D mutations using colon tissue sections of these patients by immunohistochemistry. All mutants
presented increased protein expression in smooth muscle layer of ganglionic segments. Moreover, A131T-SEMA3A also
maintained higher protein levels in the aganglionic muscle layers. These findings strongly suggest that these mutants have
a pathogenic effect on the disease. Furthermore, because of their coexistence with RETmutations, our data substantiate the
additive genetic model proposed for this rare disorder and further support the association of SEMAs genes with HSCR.
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Introduction
Hirschsprung disease (HSCR, OMIM 142623) is a devel-
opmental disorder occurring in 1 of 5,000 live births. HSCR
most commonly presents as isolated cases and displays a
complex pattern of inheritance with low, sex dependent
penetrance and variable expression. It is characterized by the
absence of ganglion cells along variable lengths of the distal
gastrointestinal tract, which results in tonic contraction of the
aganglionic colon segment and functional intestinal obstruc-
tion. Such aganglionosis is attributed to a failure of neural crest
cells (NCC) to migrate, proliferate, and/or differentiate during
enteric nervous system (ENS) development in the embryonic
stage [1,2].
The RET proto-oncogene (OMIM 164761) is the major gene
associated to HSCR. RET has been extensively studied in
HSCR patients and over 100 mutations have been identified
along the gene (see Human Gene Mutation Database).
However, mutations in the RET coding sequence account for
only up to 50% or 7–20% of familial and sporadic cases,
respectively [2]. The involvement of RET in the pathogenesis
of HSCR is further supported by the existence of a specific
haplotype, constituted by common RET polymorphisms, which
seems to be responsible for the majority of sporadic forms
[3,4,5]. This HSCR-associated RET haplotype is characterized
by a common allele (c.73+9277T, rs2435357) within a
conserved enhancer-like sequence in intron 1 (MCS+9.7)
[5,6], making a 20-fold greater contribution to risk than
coding mutations [5]. It has been demonstrated a difference in
ability of SOX10 to bind to MCS+9.7 and transactivate RET
depending on the bearing allele at such specific locus [6].
On the other hand, numerous molecular genetic studies have
identified rare coding mutations in many other genes (GDNF,
NRTN, PSPN, EDNRB, EDN3, ECE1, NTF3, NTRK3, SOX10,
PHOX2B, L1CAM, ZFHX1B, KIAA1279, TCF4, PROK1, PROKR1,
PROKR2, GFRA1, NRG1 and SEMAs) related to HSCR [2,7–13].
However, the conventional mutations related to HSCR reported
so far only explain around 5% of cases, being the vast majority of
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them long segment HSCR and/or total colonic aganglionosis and
syndromic forms of the disease [2].
HSCR is regarded as a complex and multifactorial genetic
disorder, in which the contribution of several different loci acting
in an additive or multiplicative manner is usually required to cause
the disease [3]. Based on this evidence, several HSCR-associated
regions (9q31 [14], 19q12 [15], 3p21 [15,16], 16q23 [17], 21q21
[18], or 4q31.3-q32.3 [19]) have been identified by genome wide
linkage and genome wide association studies (GWAS), although
the genes underlying such associations have not been identified yet
in most of the cases.
Through a GWAS performed by the International HSCR
Consortium, in which our group takes part, a significant cluster of
SNPs was identified in a region on chromosome 7, containing
strong association with HSCR with allelic effects independent of
RET, that fell downstream from the protein SEMA3D (7q21.11;
OMIM 609907) and upstream from SEMA3A (7p12.1; OMIM
603961) (S. Arnold et al., 2ndInternational Symposium: Development of the
Table 1. SEMA3A sequence variants detected in the current study.
Nucleotide Change Aminoacid Change Novel/Described
Allelic frequency (%) in control
population
c.112+52del Novel 0
c.112+52 C.G Novel 0
c.112+63 T.C rs13231702 0
c.113-110 A.C rs12671857 52.2
c.113-42 G.C rs17241389 0
c.201T.C S67S Novel 1
c.267A.G Q89Q Arnold et al., 2009 0
c.270+96A.G Novel 0
c.333+84T.A Novel 0
c.333+92G.T rs6955597 0.3
c.334-24delTT Novel 0
c.391G.A A131T rs143007146
c.453+24A.G rs1990044 47.9
c.547+167G.A rs2527039 15.8
c.548-45C.T Novel 0
c.548-67T.C Novel 1
c.548-79G.C Novel 0
c.548-92 T.C Novel 0
c.668-199_201del Novel 2.5
c.668-138A.T Novel 0
c.668-20 C.T rs2272221 10.5
c.668-14 T.A rs2272222 2.2
c.705T.C S235S rs34541339 6.8
c.732C.T Y244Y Novel 0
c.811-139C.T Novel 0
c.945C.T N315N Novel 0
c.1140+46C.G Novel 0
c.1302T.C I434I Novel 15
c.1303G.A V435I Arnold et al., 2009 3
c.1361-52T.A rs10250165 23.8
c.1361-14A.G rs3735513 14.7
c.1453-9delA Novel 0
c.1495+132A.C rs17246251 61.5
c.1563G.C G521G rs10487865 0
c.1652-85insTA Novel 0
c.1653-6C.T rs701320 84
c.1792A.G S598G Novel 0
c.1860+30A.G rs7809708 26.5
c.2151A.G T717T rs797821 32.5
Compilation of all the SEMA3A sequences variants found by dHPLC. Note that the missense variants are shaded.
doi:10.1371/journal.pone.0054800.t001
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ENS: Cells, signals and genes. Feb 2009). In such study, short-HSCR
trios were analyzed with the 500K SNP array platform (Affyme-
trix) and the SEMA SNPs cluster was identified and subsequently
refined. The two SEMA family III members demonstrated very
similar temporo-spatial patterns of expression throughout the
colon. Notably, they were co-expressed with RET in this tissue,
supporting the possibility that any of them might modify RET
function in the developing ENS.
In addition, based in these findings, next-generation sequenc-
ing technologies and functional analyses have allowed the
identification of semaphorins class III genes (SEMAs) 3A and
3D mutations potentially involved in the pathogenesis of HSCR
[13].
SEMAs represent the largest family of axonal guidance cues
identified so far, that provides directional information to growing
axons. The role of SEMAs pattering sensory projections in the
peripheral [20] and central nervous system [21] is well known.
Previous studies have also suggested a role for members of the
SEMA family in NCC development, proliferation, migration,
and/or differentiation, which are processes related with HSCR
etiology [22–25]. More specifically, SEMA3A is expressed in the
mesenchyme of distal large intestine and it also acts as a repulsive
signal for neurites of Remak ganglia [26]. Although ENS
precursors derived from sacral NCCs express the receptor
Neuropilin1 (NP1), it remains to be demonstrated if SEMA3A
acts on migration by a direct effect on the migrating ENS
precursors, or by an indirect action over extrinsic axons that
accompany those cells when colonizing the bowel, and are
repelled if SEMA3A is present in the outer segments of colon
mesenchyme [22]. More recently, different in vitro and in vivo
approaches reinforce the important role of SEMAs and their
receptors as key players in the immunological and the neurolog-
ical systems [27–29].
Furthermore, it has been proposed that increased SEMA3A
expression may be a risk factor for HSCR pathology in a subset of
HSCR patients, based on the upregulation of this gene in the
aganglionic smooth muscle layer of the colon [30]. In addition, the
association between two SEMA3A polymorphisms (rs7804122 and
rs797821) and the risk of HSCR in the Northeastern Chinese
population has been validated, as it was previously demonstrated
in Caucasian population [31]. Based on the evidences of the
implication of SEMA class III genes in HSCR, we have performed
a screening of the coding region of SEMA3A and SEMA3D genes
in a series of 200 isolated Spanish HSCR cases, to determine their
mutational spectrum in our population. Three mutations, A131T-
SEMA3A, S598G-SEMA3A and E198K-SEMA3D were further
studied using an immunohistochemical approach to evaluate their
expression levels in the HSCR samples. All mutants presented an
increased amount of the proteins in colon tissue sections in
comparison with the normal proteins, indicating the pathogenic
role of these mutations.
Materials and Methods
Patients and Controls Subjects
In this study we have included a total of 200 Spanish HSCR
patients (23% female, 77% male), and their parents when
available. 180 were sporadic cases, while 20 were familial cases
belonging to 13 different families. In addition, we have also
analyzed a group of 200 normal controls comprising unselected,
unrelated, race, age, and sex-matched individuals.
Ethics Statement
A written informed consent was obtained from all the
participants for clinical and molecular genetic studies. The
study conformed to the tenets of the declaration of Helsinki as
Table 2. SEMA3D sequence variants detected in the current study.
Nucleotide Change Aminoacid Change Novel/Described
Allelic frequency (%) in control
population
c-151-158_154del Novel 1
c.376-32G.A Novel 0
c.496-12T.C Novel 0
c.589+37G.A rs17159594 0
c.590-33T.A Novel 3.5
c.718+26T.C Novel 0
c.636C.T D212D Novel 0
c.592G.A E198K Novel 0
c.861+67_71del rs56131427 4.8
c.1545+91G.A rs7780132 28.3
c.1546-9 G.A Novel 0
c.1578C.T L526L rs17559084 43.8
c.1703+28G.C rs6468008 27
c.1843C.A P615T Novel 0.5
c.1901G.A R634Q TMP_ESP_7:84636125* 0
c.1906+147T.C Novel 0
c.2103G.T K701Q rs7800072 35.8
Compilation of all the SEMA3D sequences variants found by dHPLC. Note that the missense variants are shaded.
*Source: Ensemble.
doi:10.1371/journal.pone.0054800.t002
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well as the requirements established by our Institutional Review
Board.
Mutational Analysis
Genomic DNA was extracted from peripheral blood leukocytes
from all the individuals included in the study, using standard
protocols. The mutational screening of the complete coding
sequence of SEMA3A and SEMA3D was carried out by denaturing
high-performance liquid chromatography in a WAVE DNA
Fragment Analysis system (Transgenomic). Those fragments with
aberrant profiles were subjected to sequence analysis using an ABI
PrismH3730 Genetic Analyzer and the SeqScapeH v2.5 software
(Applied Biosystems). When a change was detected, the appropri-
ate DNA fragment was also screened in a group of 200 normal
controls to determine its allelic frequency in our population.
Primers and PCR-dHPLC conditions used are avaliable under
request.
Immunohistochemistry (IHQ)
Formalin-fixed paraffin embedded (FFPE) colon tissue blocks
were collected from patients with the following mutations:
A131T-SEMA3A (both ganglionic and aganglionic sections),
S598G-SEMA3A and E198K-SEMA3D (only ganglionic tissues).
Unfortunately, no material from patients with R634Q-SEMA3D
mutations was available. Four mm thick paraffin sections were
dewaxed in xylene and rehydrated in a series of graded alcohols.
Endogenous peroxidase activity was blocked with water contain-
ing 3% H2O2 for 30 minutes. Antigen retrieval was done by
microwaving using citrate phosphate buffer (pH 6.0). Sections
were incubated at 4uC overnight with the primary antibodies
anti-SEMA3A (1:50 dilution, anti-rabbit, AntibodyBcn, Barce-
lona, Spain) and anti-SEMA3D (1:5 dilution, anti-rabbit, Novus
Biologicals, Cambridge, UK). After several washes in Tris buffer,
peroxidase-labelled secondary antibodies and 3,39-diaminobenzi-
dine were applied to develop immunoreactivity, according to
manufacturer’s protocol (EnVision; Dako, Glostrup, Denmark).
The slides were then counterstained with hematoxylin and
mounted in DPX (BDH Laboratories, Poole, UK). Colon tissue
section in which primary antibody was omitted was used as
negative control.
Results and Discussion
Members of SEMA class III protein subfamily are inhibitory
axon guidance molecules, which could help to determine the
axonal projection patterns of several neurons and ganglia
throughout the central and peripheral nervous system [32].
Moreover, SEMA3A has been related to HSCR through different
approaches [13,30,31].
We have detected a total of 56 sequence variants in the
mutational screening of SEMA3A and SEMA3D genes (Tables 1
and 2). The most interesting finding among these results was
the detection of four missense variants (SEMA3A: A131T,
S598G; SEMA3D: E198K, R634Q) in heterozygosis. Two of
them were already described (A131T-3A with a MAF = 0,01
and R634Q-3D with a MAF = 0,0093) in public databases
(1000 Genomes, EVS and NCBI) but the other two (S598G-3A
and E198K-3D) were novel. All four variants are located in the
coding region of both SEMA proteins and found exclusively in
HSCR series but absent in the control population (Table 3).
They were detected with a mutational frequency range of
0.005%-0.01%, which was comparable with the percentages of
SEMA mutations previously described in Caucasian population
(0.004%–0.011%) [13].
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There are several evidences that led us to propose the four
missense variants in two SEMAs genes (SEMA3A: A131T, S598G;
SEMA3D: E198K, R634Q) as mutations associated to HSCR.
First, the mutations were detected in two main protein domains
(Figure 1): the SEMA domain, which is important for protein-
protein interaction (A131T-SEMA3A and E198K-SEMA3D) and
the domain implicated in receptor binding (S598G-SEMA3A and
R634Q-SEMA3D). Second, in silico predictions (SIFT, Polyphen)
had shown the damaging effect of those four mutant proteins.
Here, we have also partially characterized the mutations A131T-
SEMA3A and S598G-SEMA3A and E198K-SEMA3D by immu-
nohistochemistry. In histological analyses, both SEMA3A (Figure 2)
and SEMA3D (Figure 3) were expressed in the ganglion cells of the
myenteric and submucosal plexuses as well as in the smooth
muscle layers of the ganglionic colon of our patients and in the
control samples.
Regarding the A131T-SEMA3A mutation, we obtained both
ganglionic and aganglionic segments from the patient. A highly
expressed mutant SEMA3A protein in the smooth muscle layers in
the aganglionic segment was detected. This increased amount of
protein seemed to be higher than the increase found in both the
corresponding ganglionic segment and the control sample
(Figure 4). This is in accordance with previously published results
for the wild type SEMA3A protein, that it is upregulated in the
aganglionic colon tissue [30].
In the case of S598G-SEMA3A and E198K-SEMA3D
mutants, a more intense immunostaining in all ganglionic
tissue layers in comparison with the control sample was
detected (Figure 4).
Based on the increased amount detected of both SEMA3A and
SEMA3D proteins in colon tissue of HSCR patients, we propose
that those variants results in the accumulation of SEMAs proteins
leading to impaired enteric axonal projection during NCCs
migration and/or differentiation, with functional consequences
in ENS formation. Given the role of SEMAs as crucial modulators
during embryonic development [32], abnormal SEMAs expression
or function may have a pleiotropic effect, as it has been observed
in mouse null mutants of genes encoding SEMA3A and its receptor
NP1 [33]. This hypothesis fits with the lack of null mutations in our
mutational screening, being more plausible that the missense
mutations detected on SEMA3A and SEMA3D genes cause a more
subtle effect on protein function than null mutations do. Thus, we
propose that the genetic background of the individual in
combination with the presence of those hypomorphic mutations
in the SEMA genes would generate the specific phenotype
observed in our patients, in accordance with the additive model
previously proposed for HSCR [34]. We failed to detect any other
coding mutation in the previously associated HSCR genes in the
patients with SEMA mutations (data not shown), except for RET
and EDNRB genes (Table 3), although we cannot discard the
contribution of additional mutational events in still unidentified
HSCR genes.
It is worth of mention the high incidence of co-occurrence of
coding RET mutations and SEMA3A mutations in our series of
patients, as 50% of the patients with mutations on this locus
present coding mutations in RET. All patients carrying
mutations either in SEMA3A or SEMA3D genes have inherited
Figure 1. Schematic domain location of the mutations analyzed in human Sema3A and Sema3D proteins. An N-terminal seven-bladed
b-propeller Sema domain followed by a cysteine-rich PSI (plexin, semaphorin, integrin) domain is a signature feature in the ectodomains of
semaphorin and plexin family members. The composition of the remainder of the semaphorin ectodomain varies according to class: the ectodomains
of the secreted class 3 semaphorins contain an Ig (immunoglobulin-like) domain and a basic C-terminal tail.
doi:10.1371/journal.pone.0054800.g001
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Figure 2. Immunostaining of Semaphorin 3A in colon from controls and HSCR patients. The SEMA3A staining illustrated that the
expression was present at smooth muscle (D, E, F) and submucous (G, H, I) layers, as well as in myenteric (J, K) and submucous plexuses (M, N) either
in normal colon (A, D, G, J, M) and patients with A131T-3A (B, E, H, K, N) and S598G-3A mutations (C, F, I). The FFPE tissue block from patient with
S598G had no all tissue layers. Scale bars: A–C= 200 mm and the rest of pictures = 10 mm.
doi:10.1371/journal.pone.0054800.g002
New Semaphorins Variants in HSCR Patients
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e54800
either RET enhancer variant or a coding mutation associated
to HSCR.
It is well established that activation of RET is essential for
proliferation, migration and differentiation of enteric neural
precursors [35]. The vast majority of enteric neurons and glial
cells arise from vagal NCCs, although sacral NCCs also give rise
to some neurons and glia, principally in the distal hindgut, after
the caecum [36,37]. Migration of enteric precursors derived from
vagal NCCs, within the colon has been shown to depend mainly
on the proliferation at the migration wave front, rather than on
the presence of factors that promote migration [38]. For that
reason, mutations in RET cause a failure of those cells to colonise
the distal colon in an appropriate number to form the enteric
ganglia, leading to HSCR [2]. The expression of GDNF in the
hindgut is lower than in the caecum [39] and therefore many
authors have proposed that migration and proliferation of sacral
NCCs is less dependent on GDNF. In addition, sacral NCCs are
able to migrate through pre-caecum colon in a slower manner
compared to vagal derived cells [22,39–42]. In such scenario, we
propose that the absence of enteric ganglia in the distal part of
the bowel, due to a fail of vagal NCCs, could be rescued by the
migration and differentiation of sacral NCCs. It has been
demonstrated that SEMA3A regulates the entry of extrinsic axons
into the hindgut and also sacral NCCs, as they accompany those
axons when migrating to the colon. In fact, defects on SEMA3A
expression impair the entry of sacral enteric precursors in the
hindgut [22]. For that reason, we suggest that a fail on sacral
NCCs to colonize the hindgut in the appropriate moment, due to
the presence of mutations in SEMA3A, would results in a more
dramatic phenotype in patients also harbouring mutations in
RET, as SEMA3A has no effects on vagal NCCs [22]. In
agreement with this hypothesis, we did not observe an enteric
phenotype in family members of our HSCR patients with isolated
mutations in RET or SEMA3A. Segregation analysis for these
mutations in both genes together with the available data of
mutations in other genes associated to HSCR, led us to speculate
with the potential synergistic effect of mutations in both RET and
SEMA genes. We believe that the major contributing mutation
could be either on RET or SEMA, or in both genes at the same
time alone or together with some other mutations in unknown
genes, due to the complexity of the genetic basis of HSCR and
the additive model proposed for the disease. Future analyses will
be needed to clarify the role of both genes.
In summary, in this study we have analyzed three aminoacidic
substitutions, A131T-SEMA3A, S598G-SEMA3A and E198K-
SEMA3D. These variants result in an increase of SEMA proteins
levels in the HSCR colon tissue. Our findings further support the
functional implication of SEMAs as signalling molecules in the
development of ENS and indicate a synergistic effect of mutations
in both SEMA and RET genes, to influence the phenotype of our
HSCR patients.
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Figure 3. Immunostaining of Semaphorin 3D in colon from
controls and HSCR patients. The SEMA3D staining illustrated was
present at smooth muscle (C, D) and submucous (E, F) layers, as well as
in myenteric (G, H) and submucous plexuses (I, J) either in normal colon
(A, C, E, G, I) and patients with E198K-3D mutation (B,D, F, H, J). Scale
bars: A, B = 200 mm and the rest of pictures = 10 mm.
doi:10.1371/journal.pone.0054800.g003
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Figure 4. Immunohistochemical detection of A131T-SEMA3A, S598G-SEMA3A and E198K-SEMA3D mutant proteins in FFPE colon
samples. Immunohistochemistry analysis of A131T-3A, S598G-3A and E198K-3D mutant proteins in smooth muscle layer of control samples (3A: A,
D; 3D: H, K) and colon tissue from patients with A131T-3A (ganglionic: B, E; aganglionic: C, F), S598G-3A (G, J) and E198K-3D mutations (I, L) was
performed. Scale bars: A, B, C, G, H, I = 200 mm and the rest of the pictures = 10 mm.
doi:10.1371/journal.pone.0054800.g004
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